Preparation and Evaluation of Rizatriptan Benzoate Loaded Nanostructured Lipid Carrier Using Diff erent Surfactant/Co-Surfactant Systems

Abstract

Migraine is the second most common neurological illness, aff ecting around one billion people each year; triptans are commonly used in the treatment; rizatriptan benzoate is a member of the triptan class, it’s available as a tablet dosage form. Unfortunately, it undergoes fi rst-pass eff ect after oral intake. The intranasal route of administration represents a solve to such a problem. Because it has a limited permeability, an eff ort has been made to circumvent this hurdle. Nanotechnology’s innovation has off ered a useful answer to several issues in the pharmaceutical fi eld in which it could improve drug permeability. The aim of the present work involved loading rizatriptan benzoate on a nanostructured lipid carrier as an attempt to resolve adversity affi liated with the intended drug. The high-speed homogenization technique prepares six formulas. The formulations’ particle size, polydispersity index, zeta potential, entrapment effi ciency, loading capacity, and in-vitro drug release were studied. Diff erential scanning calorimetry (DSC), Fourier transforms infrared spectroscopy (FTIR), and powder X-ray diff raction (PXRD) was investigated to exclude drug excipient incompatibility and to evaluate the crystallinity state of rizatriptan benzoate before and after formulation. Successful formulations were obtained with an acceptable nanostructured parameter In-vitro drug release profi le illustrates a biphasic pattern in which an immediate followed by a persistent phase over a 6 hours. release period, with an estimated percent of the medication being released with an anomalous release mechanism. The compatibility and crystallinity investigation revealed that rizatriptan benzoate was compatible with the other excipients used in the research, and the drug molecule was found to be in an amorphous state within the lipid matrix. In conclusion, nanostructured lipid carriers might be a potential delivery approach for improving intranasal administration of rizatriptan benzoate.